New draft policy “violates integrity” of Indian pricing, says industry
This article was originally published in SRA
Executive Summary
India has unveiled a new draft national pharmaceutical pricing policy, which rewrites the rules of price regulation in the country and marks a shift from the nearly four decades-old cost-based approach to a market-based one1-3. The new policy is expected to extend dramatically the reach of price controls.